Joint Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer's Disease Cortex Reveals Altered miRNA Regulation by Nunez-Iglesias, Juan et al.
Joint Genome-Wide Profiling of miRNA and mRNA




1, Todd E. Morgan
2, Caleb E. Finch
2*, Xianghong Jasmine Zhou
1*
1Molecular and Computational Biology, University of Southern California, Los Angeles, California, United States of America, 2Davis School of Gerontology, University of
Southern California, Los Angeles, California, United States of America
Abstract
Although microRNAs are being extensively studied for their involvement in cancer and development, little is known about
their roles in Alzheimer’s disease (AD). In this study, we used microarrays for the first joint profiling and analysis of miRNAs
and mRNAs expression in brain cortex from AD and age-matched control subjects. These data provided the unique
opportunity to study the relationship between miRNA and mRNA expression in normal and AD brains. Using a non-
parametric analysis, we showed that the levels of many miRNAs can be either positively or negatively correlated with those
of their target mRNAs. Comparative analysis with independent cancer datasets showed that such miRNA-mRNA expression
correlations are not static, but rather context-dependent. Subsequently, we identified a large set of miRNA-mRNA
associations that are changed in AD versus control, highlighting AD-specific changes in the miRNA regulatory system. Our
results demonstrate a robust relationship between the levels of miRNAs and those of their targets in the brain. This has
implications in the study of the molecular pathology of AD, as well as miRNA biology in general.
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Introduction
Neurodegeneration and dementia in Alzheimer’s disease (AD)
are associated with neurotoxicity of the amyloid-beta peptide,
which accumulates as amyloid fibrils in senile plaques character-
istic of AD, and as oligomers that directly bind to neurons [1–3].
The production and clearance of the amyloid-beta peptide is
therefore a major target of investigation on the pathogenesis of AD
and therapeutic interventions for prevention and treatment. With
the exception of the rare familial forms caused by dominant
mutations, the initiating factors in most cases of AD remain
unresolved. A major clue was given by Down’s syndrome, in which
trisomy of chromosome 21 results in early onset of AD, but not in
a case in which chromosome 21 had a mosaic deletion of the
amyloid precursor protein (APP) locus [4]. This evidence
highlighting the importance of gene dosage in AD is one of the
rationales for the study of gene expression in AD brain.
Many studies have therefore examined changes in mRNA
prevalence in the brain in later stages of AD (reviewed in [5]).
There is, however, surprisingly little agreement between the
differentially expressed gene lists of different studies. Furthermore,
among the few RNA changes that are shared among expression
studies, there is no clear functional relationship. A future challenge
is to integrate large amounts of data in a network context, for
which studies such as OSCAR [6] may be a useful model.
Besides mRNA populations, microRNAs (miRNAs) may also be
important in AD. MicroRNAs are short non-coding RNAs
(*22nt long) that bind complementary sequences in target
mRNAs and can thus cause their selective degradation, or
selective inhibition of translation [7,8]. Although miRNAs have
been intensely studied in the context of cancer progression, their
role in AD has received less attention [9–12]. The most detailed of
the existing studies [10] showed decreased levels of miR-29a/b in
AD, which was predicted to cause increased levels of beta-amyloid
cleaving enzyme 1 (BACE1), an essential protein in the generation
of beta-amyloid from APP, and this prediction was confirmed in
vitro. Using oligonucleotide arrays followed by targeted experi-
ments, Wang et al [12] showed decreased levels in AD of miR-107,
which also targets BACE1.
In the present study, we used microarrays to simultaneously
measure the levels of miRNA and mRNA in the parietal lobe (Pl)
cortex of AD patients and age-matched controls. Prior studies of
specific miRNAs suggested that some miRNAs directly decrease
the levels of target mRNAs on a genome-wide scale [13–16].
Starting from genome-wide miRNA and mRNA expression data,
we devised a novel permutation scheme to robustly determine the
significance of any correlation between levels of miRNAs and
their target mRNAs. Although the levels of around 20 miRNAs
showed a significant negative correlation with those of their
targets, we were surprised to findam u c hl a r g e rn u m b e r ,o v e r5 0 ,
positively correlated with their targets. We further showed that
mRNAs involved in specific processes, such as fatty acid
metabolism and protein refolding, are responsible for this
correlation signal, and confirmed that these processes are specific
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e8898to the brain by comparison to a publicly available dataset of
cancer cell lines [17] and one of primary breast cancer cells [18].
Finally, using the permutation approach separately in the AD and
in the control samples, we were able to detect a large set of
changes in the miRNA-target correlations in AD brain. This
points to changes in the miRNA regulatory system in Alzheimer’s
disease.
Results
Differentially Expressed miRNAs and mRNAs
Total RNA was extracted from the parietal lobe cortex of 10
individuals (5 AD patients and 5 age-matched control subjects).
After RNA quality control, however, only 8 samples (4 from each
group) were used in the final study. Although these are too few to
draw any reliable conclusions about differential expression of
hundreds of miRNAs and mRNAs, we briefly present that analysis
for completeness and as a resource for future meta-analyses. We
used the empirical Bayes procedure [19] to determine the
statistical strength of possible changes in RNA prevalence, and
found 48 differentially expressed miRNAs and 11 differentially
expressed mRNAs at a False Discovery Rate [20] of 0.05 (see
Table S1 and Table S2).
For the functional analysis of the differentially expressed
miRNAs, we predicted the functions of miRNAs to be the
functions overrepresented among their targets (hypergeometric p-
value ƒ0.01). The predicted functions can be found in Table S3
(biological process), Table S4 (molecular function), and Table S5
(cellular component). Overrepresented functions among signifi-
cantly upregulated miRNAs included plasma membrane (p-value:
3:2|10{5), cell adhesion (p-value: 9:1|10{5), transmembrane
receptors (0.0065), and transmembrane transporters (0.0086).
No overrepresented functions were found among the differen-
tially expressed mRNAs.
Correlation between Expression Levels of miRNAs and
Target mRNAs
Much evidence shows that mammalian miRNAs, like their plant
counterparts, can influence gene expression not only by inhibiting
protein translation, but also by causing the degradation of their
target mRNA [14–16]. We therefore looked for negative
correlation between the expression levels of miRNAs and their
predicted target mRNAs. For individual miRNA-target pairs, our
data did not support this hypothesis: after multiple-testing
correction, no pairs passed the 0.05 FDR level.
We then tried to detect potentially subtle correlations by
deriving global statistics about miRNA-target expression correla-
tions. If high levels of a miRNA were degrading some target
mRNAs, we would expect that, among all miRNA-target
expression correlations, there would be a measurable bias towards
negative correlations. To test this, we calculated the mean
expression correlation among all miRNA-target pairs, then
repeated the calculation after randomizing the miRNA targeting
predictions. Instead of a negative correlation bias, this permutation
analysis showed a significant bias towards positive correlations
(Figure 1A). The average correlation among 240,758 miRNA-
target pairs in our data (with a ddG threshold of {15 kcal/mol for
PITA) was 0.00328, compared to a mean correlation among
permuted pairs of 0.000836. This shift had a two-sided empirical
p-value of 0.002 among 1,000 permutations. (These results are
qualitatively identical over a range of ddG thresholds; see Figure
S2.)
We were initially surprised to find positive correlations between
levels of miRNAs and their target mRNAs. Because two recent
studies [13,21] found that, for some miRNAs, miRNA levels affect
target mRNA levels only for high-prevalence mRNAs, we
repeated the analysis, but using only mRNAs with relatively high
average expression values. Indeed we found a striking change from
a positive correlation shift over all miRNA-target pairs to a
Figure 1. Permutation of miRNA-mRNA target relationships reveals a positive correlation between miRNAs and their targets, or
negative for some high-prevalence mRNAs. (A) Histogram of permuted values of mean correlation between levels of miRNAs and those of their
target mRNAs. Red arrowhead indicates true value. (2-sided p-value: 0.002) (B), (C) Weighted correlation shift (W) and sign(W)(1{p) for a range of
cutoffs of log (base 2) mRNA mean expression. (D), (E) Histogram of permuted values for mRNA log-expression cutoffs 4 and 11. (All plots were
generated using a ddG cutoff of {15 kcal/mol.)
doi:10.1371/journal.pone.0008898.g001
Joint miRNA, mRNA Expr. in AD
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mean mRNA expression levels of 11 or greater (log2 scale) (p-
value = 0.002 after 1000 permutations) (Figure 1) (log mRNA
expression levels range from 2 to 15; see Figure S1 for the full
distribution).
Individual RNAs Involved in the Correlation Shift
We detected an overall bias in miRNA-target correlations
towards positive correlations, relative to a permuted distribution.
We wished to determine whether the bias was due to a few
miRNAs having a strong correlation with their targets, or most
miRNAs having a weak correlation with their targets. In the first
case, we would expect an essentially uniform distribution of p-
values with a strong peak near zero. In the second case, we would
expect a skewed p-value distribution.
The observed distributions of empirical p-values for both
miRNAs and mRNAs are shown in Figure 2. (An equivalent
figure using the TargetScan miRNA target prediction method is
shown in Figure S3, which shows that this result is robust with
respect to the prediction method used.) These histograms reveal
that most miRNA-mRNA pairs are actually uncorrelated, with
only about 60 miRNAs and 400 mRNAs contributing to the
positive correlation bias detected among all pairs. Interestingly,
despite a positive correlation on average among all miRNA-target
pairs, we also found strong peak of about 20 negatively correlated
miRNAs and 300 negatively correlated mRNAs. Therefore, the
positive correlation average masks distinct populations of positively
and negatively correlated miRNA-target pairs, and it is the relative
abundance of positive and negative correlations that drives the
average.
Having determined that only relatively few miRNAs actually
exhibit correlations with their targets (whether positive or
negative), we show the 10 most positive miRNA-target pairs in
Table 1 and the 10 most negative pairs in Table 2. Note that no
correspondence should be inferred between the miRNAs and
mRNAs in these two tables: the presence of an RNA in either table
is the result of summing over many correlations. Since miRNAs
can target hundreds or even thousands of mRNAs, no individual
correlations can by itself much affect the W-score, and conversely,
a high W-score does not imply high correlation across all a
miRNA’s targets. The full data of weighted correlation shifts can
be found in Tables S6 and S7. Additionally, we used miRNA-
mRNA concordance (see Methods, ‘‘MicroRNA-mRNA mutual
concordance score and differential mutual concordance score’’
below) to generate pairs of miRNA-targets in which both RNAs
had high W-scores and were highly correlated to each other (Table
S8).
To analyze the functions of those highly correlated (positively or
negatively) miRNAs and mRNAs, we generalized the idea of
weighted correlation shift from RNAs to groups of RNAs, in this
case defined by GO biological processes. We then asked whether
RNAs involved in some biological processes exhibit particularly
high or low correlations. Among the processes most positively
correlated with their regulating miRNAs, we found some very
specific processes, including metabolism of both carbohydrates
and fatty acids, as well as protein refolding, indicating the
particular importance of these processes in the brain. Among the
processes most negatively correlated are general regulatory
functions such as RNA splicing and translational elongation
(which could indicate an interesting self-regulatory loop in miRNA
function), but also more specific processes that could play a role in
AD brain, such as oxygen transport, cell adhesion, inflammatory
response, cytoskeletal organization and dendrite development (see
Table S9).
Comparison to Other miRNA/mRNA Datasets
To further validate these new methods, we examined the
correlation shift in two other miRNA/mRNA expression datasets:
the NCI-60 cell line panel [17], and a panel of primary breast
tumor cells [18].
The NCI-60 dataset displayed an overall negative correlation
bias throughout the range of expression values (Figure 3; see
Figure S4 for the distribution of expression values), and an entirely
different set of miRNAs and Gene Ontology biological processes
associated with the correlation bias. For example, the most highly
correlated processes in the NCI-60 panel are ‘‘hepatocyte growth
factor receptor signaling pathway’’, ‘‘myoblast proliferation’’,
‘‘regulation of cytokine-mediated signaling pathway’’, ‘‘immune
response-regulating signaling pathway’’, ‘‘chemokine receptor
transport within lipid bilayer’’, ‘‘regulation of transcription from
RNA polymerase II promoter by carbon catabolites’’, and ‘‘UV
protection’’ (Table S10). None of these are positively or negatively
correlated in the brain samples. Note that even in this case, there
are distinct miRNA-target populations that are either positively or
negatively correlated (Figure 3, panels C and D); the overall
average correlation is negative because the relative abundance of
positively and negatively correlated pairs is inverted compared to
that in our dataset. This result implies that our method can find
active miRNA-mRNA relationships in their specific context, and
that, as expected, these active relationships are different between
cancer cell lines and brain cells.
Figure 2. Histograms of miRNA- and mRNA-level p-values.
mRNA (RefSeq) (A) and miRNA (B) p-value histograms using mRNA log-
expression cutoff 4. The p-values are from 1,000 permutations. Here, r is
the observed mean correlation for that RNA, and r0 is the
corresponding permuted correlation.
doi:10.1371/journal.pone.0008898.g002
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correlation was not significantly shifted in either the positive or
negative direction (not shown). However, when we examined the
distribution of p-values for mRNA weighted correlation shifts, we
again found that a number of mRNAs were significantly positively
correlated with their regulating miRNAs, while a similar number
were significantly negatively correlated (Figure 4A). The histogram
of p-values for miRNAs (Figure 4B) is too noisy to draw any
conclusions from it, but this could be partly due to the low number
of represented miRNAs in this dataset (130 vs 889 in our brain
dataset and 189 in the NCI-60 dataset).
Taken together, these results suggest that miRNA-target
correlations would be detectable in most expression datasets using
our method, as we have found evidence of these correlations in
three completely independent datasets. The main difference
between datasets then seems to be whether positive or negative
correlations predominate, or neither.
Regulatory Changes between miRNAs and Target mRNAs
in Alzheimer’s Disease
The correlation shifts discussed so far are exhibited across all AD
and control samples. To identify specific correlations that may have
been gained or lost in AD brain, we repeated the permutation
analysis separately on the AD samples and the control samples, to
look for the largest changes in weighted correlation shifts. Note that
this analysis is independent of changes in expression between the
two sample groups; it instead detects changes between the groups in
correlations found within the groups, and can thus indicate changes
in miRNA function in the AD brain. To compensate for small
sample size, we exploited the many-to-many network of miRNA
targeting relationships to create a differential mutual concordance
score (see details in Methods) and thus identify the miRNA-target
mRNA pairs exhibiting the highest correlation change between AD
and control. We specifically searched for pairs that were concordant
(positively or negatively correlated with each other and with other
targets/regulators) in AD but not in control samples, and vice versa.
These pairs should indicate regulatoryrelationshipsbeing turned on
and off in AD brain.
A Mann-Whitney test comparing the ranks of pairs containing
AD-related genes (defined by GeneRIF [22]) to those containing
genes unrelated to AD gave a p-value of 3:503|10{6, indicating
that differential concordance analysis can recover miRNA-target
relationships that are functionally relevant to AD. The 40 most
changed regulatory pairs are represented as a network in Figure S5
(the full results can be found in Table S11).
Table 1. Most positively correlated mRNAs and miRNAs.
mRNAs
RefSeq ID Gene ID Gene Symbol mean n rand p W
NM_015723 50640 PNPLA8 0.174 33 {0:167 v10{3 6.35
NM_152487 148534 TMEM56 0.337 14 {0:115 v10{3 5.88
NM_007173 11098 PRSS23 0.138 28 {0:189 v10{3 5.85
NM_004849 9474 ATG5 0.088 51 {0:156 v10{3 5.71
NM_006500 4162 MCAM 0.349 80 0.103 v10{3 5.60
NM_006597 3312 HSPA8 0.841 4 {0:286 v10{3 5.55
NM_015235 23283 CSTF2T 0.034 50 {0:296 v10{3 5.50
NM_001017963 3320 HSP90AA1 0.439 12 {0:038 v10{3 5.22
NM_001199 649 BMP1 0.289 50 0.053 v10{3 5.01
NM_018710 55529 TMEM55A 0.408 8 {0:191 v10{3 5.01
MicroRNAs
miRNA ID mean n rand p W
hsa-miR-661 0.052 4037 0.022 v10{3 5.15
hsa-mir-44691 0.056 1032 {0:002 v10{3 4.85
hsa-miR-637 {0:009 6154 {0:027 v10{3 4.58
hsa-miR-657 0.081 386 0.024 v10{3 4.16
hsa-miR-34c 0.035 477 {0:036 v10{3 4.14
hsa-miR-629 0.067 206 {0:017 v10{3 4.03
hsa-mir-15903 0.086 206 0.002 v10{3 3.86
hsa-miR-615 0.057 433 {0:015 v10{3 3.73
hsa-mir-09369 0.065 324 {0:014 v10{3 3.61
hsa-miR-18b 0.138 86 0.003 v10{3 3.53
The ten mRNAs most positively correlated with their regulating miRNAs, and ten miRNAs most positively correlated with their target mRNAs, as measured by their
weighted correlation shift (W). Repeated mRNAs (RefSeq IDs that map to the same UTR and therefore the same probesets and same expression) were removed from
the table. Data was limited to mRNAs with log-expression values greater than 4. Header legend: mean: mean correlation over all targets (in the case of miRNAs) or
regulators (in the case of mRNAs); n: number of correlations included in the mean. rand: average correlation after randomization.
doi:10.1371/journal.pone.0008898.t001
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This is the first study of AD to measure mRNA and miRNA
levels in the same brain samples and supports the potential role of
miRNAs in AD pathogenesis. We found a substantial number of
new differentially expressed miRNAs at an FDR of 0.05. The
expression of 5.4% of sampled miRNAs was affected by AD at this
statistical significance level, suggesting a new approach to the
molecular analysis of AD. We found a strong concordance
between the miRNAs with differential expression in AD cortex as
found in our study and in that of He ´bert et al [10]. Of the 16
miRNAs they reported, 5 were found in our set of 29 differentially
expressed (non-predicted) miRNAs, and all in the same direction
(p-value: 0.0084). Results on differentially expressed miRNAs in
AD [9,23,24] appear to be more robust and reproducible than
those of differentially expressed mRNAs [5].
Our joint miRNA-mRNA data and permutation analyses add
to the mounting evidence that miRNAs can regulate the
expression levels of target RNAs in humans. Recently, Vasudevan
et al [25] found that miRNAs can switch from repression to
activation of target translation, depending on the cell cycle state of
the cell. Based on our analysis of data in the brain (containing
predominantly cell cycle arrested cells) compared to the NCI-60
cell line data and primary breast tumor data (which consist of
actively replicating cells), we propose that this switch could occur
not only at the level of translation, but also at the level of mRNA
stability. Further, individual miRNAs appear to have different
mode of actions, since all three datasets present both positively and
negatively correlated miRNAs. Our data, however, cannot
distinguish between the regulation of mRNA levels by miRNAs
and the coregulation of both miRNAs and their targets by
upstream factors, as hypothesized by Tsang et al [26], who also
found both positive and negative correlations in their data.
Distinguishing between these two possibilities presents an exciting
avenue for future research.
In any case, it is clear that there are at least two distinct
populations of miRNA: one that positively correlates with its
targets, and another that negatively correlates with its targets.
Recent studies corroborate this finding [27,28]. The targets of the
latter population appear to include high-prevalence mRNAs that
function in general transcription and translation machinery. Few
other studies have jointly analyzed miRNA and mRNA array
data, especially in the field of AD. Notably, miR-34c, for which we
have strong evidence of positive correlation with its targets
(Table 1), was also found to be positively correlated with its targets
in mouse brain [26] and in rat oligodendrocytes [29]. miR-218,
Table 2. Most negatively correlated mRNAs and miRNAs.
mRNAs
RefSeq ID Gene ID Gene Symbol mean n rand p W
NM_014810 9857 CEP350 {0:146 84 0:073 v10{3 {6:60
NM_003012 6422 SFRP1 {0:067 68 0:189 v10{3 {6:28
NM_052854 90993 CREB3L1 {0:063 56 0:178 v10{3 {5:48
NM_006499 3964 LGALS8 {0:286 50 {0:058 v10{3 {5:40
NM_201543 {0:286 50 {0:058 v10{3 {5:40
NM_000517 3040 HBA2 {0:607 24 {0:182 v10{3 {5:10
NM_000558 3039 HBA1 {0:607 24 {0:182 v10{3 {5:10
NM_004305 274 BIN1 {0:271 40 0:016 v10{3 {4:97
NM_000873 3384 ICAM2 {0:801 4 0:107 v10{3 {4:96
NM_001008540 7852 CXCR4 {0:616 9 {0:095 v10{3 {4:88
MicroRNAs
miRNA ID mean n rand p W
hsa-miR-768-3p {0:147 113 0:005 v10{3 {4:78
hsa-miR-216 {0:426 11 0:004 v10{3 {4:21
hsa-miR-515-3p {0:320 51 {0:023 v10{3 {4:19
hsa-miR-612 {0:057 4706 {0:038 v10{3 {3:91
hsa-miR-211 {0:056 492 0:007 v10{3 {3:51
hsa-miR-325 {0:128 101 {0:014 v10{3 {3:46
hsa-mir-45496 {0:204 18 0:003 v10{3 {3:22
hsa-mir-32339 {0:203 20 0:018 v10{3 {3:18
hsa-miR-506 {0:219 56 {0:028 0:004 {2:99
hsa-mir-06164 {0:202 23 0:010 v10{3 {2:90
The ten mRNAs most negatively correlated with their regulating miRNAs, and ten miRNAs most negatively correlated with their target mRNAs, as measured by their
weighted correlation shift (W). Repeated mRNAs (RefSeq IDs that map to the same UTR and therefore the same probesets and same expression) were removed from
the table. Data was limited to mRNAs with log-expression values greater than 4. Header legend: mean: mean correlation over all targets (in the case of miRNAs) or
regulators (in the case of mRNAs); n: number of correlations included in the mean. rand: average correlation after randomization.
doi:10.1371/journal.pone.0008898.t002
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highly positively correlated miRNAs, but did have a high positive
weighted correlation shift (W~2:07,p~0:034). These may
represent cases of miRNA and mRNA coregulation in the brain
that are conserved in mammalian species, and should therefore be
considered high priority targets for future studies.
Finally, our findings of miRNA-mRNA pairs differentially
correlated between normal and AD brains point to a fine grained
level of regulation of miRNA function. Just as transcription factor
binding to target promoters has turned out to be condition-
specific, the same could be true of miRNA-target UTR pairs. Our
results demonstrate that aggregating correlation values from many
different miRNA-target pairs, and calibrating these by permuta-
tion, is an effective scheme to computationally detect relationships
between the levels of miRNAs and those of their targets on a
genome-wide scale.
Materials and Methods
Tissue Samples and RNA Extraction
Ethics statement. Postmortem human brain samples were
obtained from the USC Alzheimer’s Disease Research Center
(ADRC), which assures written informed consent from all subjects.
The USC Institutional Review Board approved the use of the
samples for this study.
RNA extraction. RNA was extracted using TriReagent from
parietal lobes of postmortem brains of five subjects with
Alzheimer’s disease and five matched controls. The average age
of subjects with Alzheimer’s disease was 85 years (range 75 to 92
years) and 91.8 years (90 to 95 years) for controls. The postmortem
interval ranged from 3.75 to 10.1h with a mean of 5.87h. Per-
sample details can be found in Table S12, and in the Gene
Expression Omnibus (see ‘‘Data Availability’’ below). We treated
Figure 3. NCI-60 overall weighted correlation shift, significance, and p-value distributions. (A) Weighted correlation shift (W)v s
minimum log (base 2) mRNA expression value. (B) Significance (sign(W):(1-p)) vs minimum log (base 2) mRNA expression value for the NCI-60 cancer
cell line dataset. (C), (D) Distribution of p-values of mRNA and miRNA
doi:10.1371/journal.pone.0008898.g003
Figure 4. Primary breast tumor p-value distributions for mRNA
(A) and miRNA (B) correlations.
doi:10.1371/journal.pone.0008898.g004
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columns (QIAGEN).
mRNA Measurements
The mRNA array measurements were performed at the UCLA
microarray core (http:// microarray.genetics.ucla.edu) and used
Affymetrix HG-U133 Plus 2.0 arrays.
miRNA Measurements
MicroRNAs were assayed by LC Sciences (Houston, TX, USA,
http://www.lcsciences.com) using a custom m-Paraflo array
containing probes for 470 miRNAs from Sanger miRBase
[30–32] and 419 miRNAs predicted by miRNAMap [33]. (Our
entire analysis pipeline was repeated without the predicted
miRNAs, and the results are qualitatively identical — see
supplementary materials.)
As quality control, we verified our miRNA measurements with
smiRNAdb [34], a mammalian miRNA expression atlas generated
by library sequencing. There is a striking agreement between our
parietal lobe measurements and their frontal lobe measurements
(an exact tissue match was not available). Of the top 25 most
highly expressed miRNAs in our data, 15 were in the top 25 in the
atlas dataset, and 23 were in the top 50. The strong agreement
between our expression values and those generated by an entirely
different quantitation method gave us confidence in the quality of
our data. In addition, we manually investigated several ‘‘brain-
specific’’ and ‘‘brain-expressed’’ miRNAs reported in the litera-
ture, and consistently found them to show high expression levels in
our data. For example, miR-124a had a mean expression level of
14.4 (log2 scale), while the full range of expression values is {4 to
16 (see Figure S1). Other examples include miR-9 with a mean
expression level of 15.7, miR-146a with 9.62, miR-134 with 9.81,
and miR-195 with 13.2.
Normalization and Analysis
We used the affy package in Bioconductor [35] to read in and
normalize the microarray measurements for each RNA type. We
used the robust multi-array average (RMA) normalization method
[36], which consists of three steps: background correction, quantile
normalization (each performed at the individual probe level), and
robust linear model fit using log-transformed intensities (at the
probeset level). We statistically evaluated changes in RNA
prevalence by the empirical Bayes (eBayes) method [19] from
the limma Bioconductor package. In a survey of methods that
estimate differential expression, Smyth [37] showed that empirical
Bayes improves specificity while having very little effect on
sensitivity.
miRNA Target Prediction
We predicted targets of both miRBase and miRNAMap
miRNAs using the Probability of Interaction by Target Accessi-
bility (PITA) method [38] developed by the Eran Segal lab. We
used a ddG cutoff of {15 for most of the presented work, but also
verified our results using a wider range of cutoffs ({5 to {15). If
there were multiple sites in a mRNA UTR, we selected only the
one with the lowest free energy change. Following the original
publication, we used a 3 nucleotide upstream flank and a 15
nucleotide downstream flank.
Repeating our study with predictions by TargetScan (context
scorev{0:3), PicTar (scorew100) or Miranda (scorew60) did
not affect the general results of this paper, with the exception of
the shift to an overall negative average correlation for high-
prevalence mRNAs.
MicroRNA Target Permutation Analysis
Our strategy for permutation first discretized the miRNA-
mRNA target relationships by applying a ddG cutoff to the PITA
predictions. In most presented analyses the cutoff was {15 kcal/
mol, but we showed that our results hold for a range of thresholds
(see Figure S2). We converted miRNA-RefSeq pairs (as returned
by PITA) to miRNA-probeset_id by using the HGU133 Plus 2.0
NA-27 table provided by Affymetrix.
The data can then be considered a bipartite graph, with nodes
representing miRNAs on one side and probesets on the other, and
edges representing PITA target prediction relationships. Nodes
have associated expression measurements. We then computed
statistics both globally (the mean correlation over all edges) and for
specific subsets of nodes (for example, the mean correlation over
all edges incident on one miRNA, or all edges incident on any
probe set annotated with a particular GO function). Finally, we
permuted the network by shuffling the edges, maintaining source
and target node degrees, but without disallowing double edges,
and recomputed statistics after shuffling. From these we can obtain
an empirical p-value and a ‘‘weighted correlation shift’’, W, which
we define as the difference between the true value and the mean





The weighted shift is identical to a Z-score, but using permuted
rather than known/parametric mean and standard deviation.
MicroRNA-mRNA Mutual Concordance Score and
Differential Mutual Concordance Score
To focus on the most specific regulatory changes in AD, we
searched for miRNA-target mRNA pairs exhibiting a high scoring
correlation shift by combining the weighted correlation shifts (W)
of miRNAs with those of their targets. We define the mutual
concordance score of a miRNA-mRNA pair as the sum of their




. (This is the expected
standard deviation of the sum of two independent Gaussian
random variables.) We then identified miRNA-target mRNA pairs
showing the highest difference in mutual concordance score





called differential mutual concordance score). To maximize
specificity, we only reported pairs with high differential mutual
concordance scores that met two additional conditions. First, the
miRNA and mRNA should both individually have high W-scores
in either AD or control samples, to prevent a single RNA with an
exceptionally high W from appearing concordant with any target/
regulator. And second, the correlation between an miRNA and
target mRNA should be in the top 30% of correlations involving
each of the RNAs, since, in an uncorrelated miRNA-target mRNA
pair, the miRNA could be correlated with other targets, and the
mRNA could be correlated with other regulating miRNAs,
resulting in a high mutual concordance score when in fact the
pair is discordant.
Note that this approach is more robust than merely calculating
the correlations between miRNAs and their targets, because those
are sensitive to biases in the samples, especially when the number
of samples is limited. In contrast, our W-score is calibrated by
permutation, eliminating many potential sources of bias in the
expression data. Our mutual concordance score is also more
powerful, since it pools information from many miRNA-target
pairs to find highly correlated individual pairs. To illustrate this, a
previous study of correlations in the NCI-60 dataset was unable to
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permutation method did (see ‘‘Analysis of a cancer cell line
dataset’’, in Results).
The differential concordance network (Figure S5) was visualized
using Cytoscape [39].
Data Availability
The expression data generated by this study are available in the
NCBI Gene Expression Omnibus (GEO) as accession GSE16759.
Supporting Information
Figure S1 Histograms of log (base 2) expression values for
mRNA and miRNA microarray data.
Found at: doi:10.1371/journal.pone.0008898.s001 (0.42 MB EPS)
Figure S2 Significance of the correlation shift (sign(W)?(1-p)) as a
function of the ddG cutoff and the mean mRNA expression cutoff
(log-base-2 scale).
Found at: doi:10.1371/journal.pone.0008898.s002 (0.52 MB EPS)
Figure S3 Histograms of miRNA- and mRNA-level p-values
using TargetScan as the miRNA target prediction method. mRNA
(RefSeq) (A) and miRNA (B) p-value histograms using mRNA log-
expression cutoff of 4. The p-values are from 1,000 permutations.
Here, r is the observed mean correlation for that RNA, and r_0 is
the corresponding permuted correlation.
Found at: doi:10.1371/journal.pone.0008898.s003 (0.46 MB EPS)
Figure S4 Histograms of log (base 2) expression values for
mRNA and miRNA microarray data in the NCI-60 dataset.
Found at: doi:10.1371/journal.pone.0008898.s004 (0.44 MB EPS)
Figure S5 MicroRNA-mRNA regulatory changes changed be-
tween normal and AD brain. The edge colorrepresents the normalized
difference between the mutual concordance scores in control and AD
samples. Red means the concordance was more positive in AD than
control, and green indicates it was more negative in AD. The edge
shape is determined by the state in AD: an arrowhead indicates a
positively correlated concordant pair in AD, a dashed line indicates a
non-concordant (uncorrelated) pair in AD, and a flat arrowhead
indicates a negatively correlated concordant pair in AD.
Found at: doi:10.1371/journal.pone.0008898.s005 (0.55 MB EPS)
Table S1 MicroRNAs differentially expressed at the 0.05 FDR
level.
Found at: doi:10.1371/journal.pone.0008898.s006 (0.00 MB
TXT)
Table S2 Messenger RNAs differentially expressed at the 0.05
FDR threshold. (Tab-delimited table.)
Found at: doi:10.1371/journal.pone.0008898.s007 (0.00 MB
TXT)
Table S3 Predicted miRNA GO Biological Processes. (Tab-
delimited table. Col1: miRNA, Col2: GO Term ID, Col3: GO
Term name. The ddG cutoff for PITA miRNA target prediction
was 215kcal/mol, and the p-value cutoff for functional enrich-
ment with the hypergeometric test was 0.01.)
Found at: doi:10.1371/journal.pone.0008898.s008 (0.03 MB
TXT)
Table S4 Predicted miRNA GO Molecular Functions. (Tab-
delimited table. Col1: miRNA, Col2: GO Term ID, Col3: GO
Term name. The ddG cutoff for PITA miRNA target prediction
was 215kcal/mol, and the p-value cutoff for functional enrich-
ment with the hypergeometric test was 0.01.)
Found at: doi:10.1371/journal.pone.0008898.s009 (0.13 MB
TXT)
Table S5 Predicted miRNA GO Cellular Components. (Tab-
delimited table. Col1: miRNA, Col2: GO Term ID, Col3: GO
Term name. The ddG cutoff for PITA miRNA target prediction
was 215kcal/mol, and the p-value cutoff for functional enrich-
ment with the hypergeometric test was 0.01.)
Found at: doi:10.1371/journal.pone.0008898.s010 (0.08 MB
TXT)
Table S6 RefSeq-level permutation results. (Tab-delimited
table. Permutation used only mRNAs with mean log-expression
greater than 4.)
Found at: doi:10.1371/journal.pone.0008898.s011 (1.51 MB
TXT)
Table S7 MicroRNA-level premutation results. (Tab-delimited
table. Permutation used only mRNAs with mean log-expression
greater than 4.)
Found at: doi:10.1371/journal.pone.0008898.s012 (0.07 MB
TXT)
Table S8 MicroRNA-mRNA highly concordant pairs.
Found at: doi:10.1371/journal.pone.0008898.s013 (7.10 MB
TXT)
Table S9 Permutation results for Gene Ontology biological
processes. (Tab-delimited table. Permutation used only mRNAs
with mean log-expression greater than 4.)
Found at: doi:10.1371/journal.pone.0008898.s014 (0.61 MB
TXT)
Table S10 Permutation results for Gene Ontology biological
processes in the NCI-60 dataset. (Tab-delimited table. Permuta-
tion used only mRNAs with mean log-expression greater than 0.)
Found at: doi:10.1371/journal.pone.0008898.s015 (0.90 MB
TXT)
Table S11 Differential concordance analysis table, including
edge ID and differential concordance scores. (Tab-delimited
table.)
Found at: doi:10.1371/journal.pone.0008898.s016 (5.49 MB
TXT)
Table S12 Information about the biological samples used in the
study.
Found at: doi:10.1371/journal.pone.0008898.s017 (0.00 MB
TXT)
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